[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-354624-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-354624-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","enzymereactive-oxygen-species-dually-activated-hyaluronic-acid-nanocarriers-enable-celastrol-delivery-for-site-specific-therapy-of-inflammatory-bowel-diseases-and-colorectal-cancer","Enzyme/Reactive Oxygen Species-Dually Activated Hyaluronic Acid Nanocarriers Enable Celastrol Delivery for Site-Specific Therapy of Inflammatory Bowel Diseases and Colorectal Cancer","","Enzyme/ROS dual-trigger hyaluronic acid nanocarriers (HA@Cel/NPs) were designed to overcome limitations of single-responsive intestinal nanocarriers and the poor oral bioavailability of celastrol for inflammation–carcinoma continuum diseases. HA@Cel/NPs were fabricated with β-cyclodextrin and 4-(hydroxymethyl)phenylboronic acid linkers, then evaluated for physicochemical behavior, enzyme/ROS-driven release, cellular uptake, anti-inflammatory effects, macrophage polarization, and anticancer activity. Oral and intravenous/intraperitoneal regimens in UC, CAC, and colon cancer mouse models demonstrated reduced inflammation and tumor burden, enhanced T-cell infiltration with anti-PD-L1, and effective eradication of established tumors.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/enzymereactive-oxygen-species-dually-activated-hyaluronic-acid-nanocarriers-enable-celastrol-delivery-for-site-specific-therapy-of-inflammatory-bowel-diseases-and-colorectal-cancer/354624/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/enzymereactive-oxygen-species-dually-activated-hyaluronic-acid-nanocarriers-enable-celastrol-delivery-for-site-specific-therapy-of-inflammatory-bowel-diseases-and-colorectal-cancer/354624.png","ImageObject",300,407,{"name":42,"@type":43},"nayy☆","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-13","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What problem does HA@Cel/NPs aim to address in intestinal diseases?","Question",{"text":63,"@type":64},"Conventional oral nanocarriers rely on single-responsive mechanisms and often target only one pathological stage, failing to cover the inflammation–carcinoma continuum. The study targets this gap while addressing celastrol’s poor bioavailability and lack of lesion-specific delivery.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How are HA@Cel/NPs engineered to trigger celastrol release?",{"text":68,"@type":64},"HA@Cel/NPs are fabricated using β-cyclodextrin and 4-(hydroxymethyl) phenylboronic acid as dual-responsive linkers, enabling enzyme/ROS-triggered release under high H2O2/α-amylase conditions.",{"name":70,"@type":61,"acceptedAnswer":71},"What therapeutic effects were observed in UC, CAC, and colon cancer models?",{"text":72,"@type":64},"In UC, oral HA@Cel/NPs alleviated disease severity; in CAC, they suppressed progression and reduced tumor burden. In colon cancer, intravenous HA@Cel/NPs combined with intraperitoneal anti-PD-L1 enhanced CD8+ and CD4+ T-cell infiltration and effectively eliminated established tumors versus monotherapy.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},354624,1790273726,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962090893153,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","International Journal of Nanomedicine  \nOpen Access Full Text Article ORIGINAL RESEARCH  \nEnzyme/Reactive Oxygen Species-Dually Activated Hyaluronic Acid Nanocarriers Enable Celastrol Delivery for Site-Specific Therapy of Inflammatory Bowel Diseases and Colorectal Cancer  \nJinfeng Shi 1 , 2 , Xueqian Zhang 1 , Linxing Yang 3 , Wei Wang 1 , Lingling Liu 1 , Tian Lu 1 , Xing Xu 1 , Yan Xu 1 , Shiyu Ren 1 , Ruifeng Luo4  \n1Key Laboratory of Structure-Specific Small Molecule Drugs at Chengdu Medical College of Sichuan Province, School of Pharmacy, Chengdu Medical College, Chengdu, Sichuan, 610500, People’s Republic of China; 2Institute of Materia Medica, Chengdu Medical College, Chengdu, Sichuan, 610500, People’s Republic of China; 3School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, 510006, People’s Republic of China; 4State Key Laboratory of Mechanism and Quality of Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Taipa, Macau, 999078, People’s Republic of China  \nCorrespondence: Ruifeng Luo; Jinfeng Shi, Email [ruifengluo128@163.com](ruifengluo128@163.com); [shijinfengss@126.com](shijinfengss@126.com)  \n\n| Introduction: Conventional oral nanocarriers for intestinal diseases rely on single-responsive mechanisms and target a single pathological stage, failing to address the inflammation–carcinoma continuum. Celastrol (Cel)’s oral translation is limited by poor bioavailability and lack of lesion-specific targeting. To overcome these barriers, we constructed a hyaluronic acid (HA)-functionalized platform featuring dual enzyme/ROS-triggered release and CD44-mediated active targeting (HA@Cel/NPs) for treating ulcerative colitis (UC), colitis-associated colorectal cancer (CAC), and colon cancer.\u003Cbr>Methods: HA@Cel/NPs were fabricated using β-cyclodextrin and 4-(hydroxymethyl) phenylboronic acid as dual-responsive linkers. Physicochemical properties, drug release profiles, cellular uptake, anti-inflammatory activity, macrophage polarization, and anticancer activity were systematically evaluated in vitro. In vivo biodistribution and therapeutic efficacy were assessed in UC, CAC, and colon cancer mouse models, with anti-PD-L1 combination therapy in the colon cancer setting.\u003Cbr>Results: HA@Cel/NPs exhibited uniform size (76.87 ± 2.65 nm, PDI 0.166 ± 0.012), stayed stable for 14 days, and achieved ~71% Cel release under high H2O2/α-amylase conditions within 8 h. The nanocarriers enhanced cellular uptake and promoted M1-to-M2 macrophage polarization in inflamed macrophages, while inducing potent CT26 cell apoptosis. Orally administered HA@Cel/NPs alleviated UC severity and suppressed CAC progression, with significantly reduced tumor burden. In colon cancer, intravenous HA@Cel/NPs combined with intraperitoneal anti-PD-L1 significantly boosted CD8+ and CD4+ T cell infiltration and effectively eradicated established tumors compared with HA@Cel/NPs monotherapy.\u003Cbr>Conclusion: HA@Cel/NPs offer a versatile, dual-route platform that bridges inflammation management and cancer immunotherapy, distinguishing itself from single-mechanism or single-disease nanocarriers.\u003Cbr>Keywords: enzyme/ROS responsive release, intestinal disease, celastrol, colon-targeted nanoplatform |\n| --- |\n| Introduction\u003Cbr>Ulcerative colitis (UC) is a chronic and relapse-prone nonspecific inflammatory disease associated with hemorrhagic diarrhea, mucosal ulcers, and weight loss.1–3 The high recurrence rate of UC not only affects 7 million people worldwide but also takes up a lot of medical resources.4 Furthermore, long-term and repeated inflammation can trigger the occurrence and progression of colitis-associated colorectal cancer (CAC) . According to reports, the lifetime risk of CAC in UC patients will be 2–4 times higher than that in the general population.5 Furthermore, CAC underscores the perpetual stimulation of epithelial cell proliferation within the inflammatory milieu. Consequently, CAC is oft","cbCaieeIpikVj0Gf","https://ap.wps.com/l/cbCaieeIpikVj0Gf","pdf",18459231,23,"English","# Introduction\n## Ulcerative colitis, recurrence, and cancer progression\n# Methods\n## Dual-responsive nanocarrier fabrication and in vitro evaluation\n## In vivo biodistribution and therapeutic efficacy models\n# Results\n## Nanocarrier characteristics and triggered drug release\n## Cellular uptake, macrophage polarization, apoptosis\n## Disease models: UC, CAC, and colon cancer with combination immunotherapy\n# Conclusion\n## Dual-route platform bridging inflammation management and cancer immunotherapy","[{\"question\":\"What problem does HA@Cel/NPs aim to address in intestinal diseases?\",\"answer\":\"Conventional oral nanocarriers rely on single-responsive mechanisms and often target only one pathological stage, failing to cover the inflammation–carcinoma continuum. The study targets this gap while addressing celastrol’s poor bioavailability and lack of lesion-specific delivery.\"},{\"question\":\"How are HA@Cel/NPs engineered to trigger celastrol release?\",\"answer\":\"HA@Cel/NPs are fabricated using β-cyclodextrin and 4-(hydroxymethyl) phenylboronic acid as dual-responsive linkers, enabling enzyme/ROS-triggered release under high H2O2/α-amylase conditions.\"},{\"question\":\"What therapeutic effects were observed in UC, CAC, and colon cancer models?\",\"answer\":\"In UC, oral HA@Cel/NPs alleviated disease severity; in CAC, they suppressed progression and reduced tumor burden. In colon cancer, intravenous HA@Cel/NPs combined with intraperitoneal anti-PD-L1 enhanced CD8+ and CD4+ T-cell infiltration and effectively eliminated established tumors versus monotherapy.\"}]","Enzyme/Reactive Oxygen Species-Dually Activated Hyaluronic Acid Nanocarriers Enable Celastrol Delivery for Site-Specific Therapy of Inflammatory Bowel Diseases and Colorectal Cancer | PDF",1790112627,58,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b1738416300f163e46d6e461ae6e627a.webp",983,1272,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/438c839426ed0f605271a5185d42c4e1.webp",982,1270,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a6b4cf4878a990f54301676fa6805567.webp",981,1269,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/063e1d32656bf3e92efba389dfe12818.webp",980,1268]